Rapid diagnostic tests (RDTs) are medical assays designed to swiftly detect specific targets, such as infectious agents or biomarkers in patient samples. One primary application lies in infectious disease management, particularly in resource-limited settings. RDTs play a critical role in promptly diagnosing diseases such as malaria, HIV, and tuberculosis, as well as emerging viruses such as Ebola and Zika. Providing quick and accurate results at the point of care enables healthcare providers to initiate timely treatment, prevent disease transmission, and implement public health interventions effectively. This application is especially vital where limited laboratory infrastructure allows rapid screening, diagnosis, and surveillance in diverse healthcare environments.
Global Rapid Diagnostic Tests (RDT) Market size is valued at USD 38,363.51 million in 2021 and is projected to reach USD 74,674.92 million by 2029 with a CAGR of 9.3% during the forecast period of 2022-2029.
To know more, visit https://www.databridgemarketresearch.com/ar/reports/global-rapid-diagnostic-tests-rdt-market
Below are the Top Rapid Diagnostic Tests Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
Abbott
|
A global leader in healthcare, Abbott offers a diverse portfolio of rapid diagnostic tests, including those for infectious diseases such as HIV, influenza, and COVID-19. Their RDT solutions are known for their accuracy, ease of use, and widespread availability, contributing significantly to global public health efforts.
|
|
South America, North America, Asia-Pacific, Europe, and Middle East and Africa
|
In February 2019, Abbott launched the most sensitive rapid diagnostic test, Determine HBsAg 2, to detect hepatitis B antigens. This test device uses whole blood, serum, and even plasma samples for the detection process. This lateral flow technology's launch helped the company enhance its platform for capillary blood collection devices.
|
|
2.
|
F. Hoffmann-La Roche Ltd.
|
Roche Diagnostics, a division of F. Hoffmann-La Roche Ltd., develops and manufactures a range of rapid diagnostic tests for various medical conditions. With a focus on innovation and quality, Roche's RDTs play a crucial role in timely disease detection and management, spanning infectious diseases, cardiovascular health, and more.
|
|
North America, Africa, Asia, Europe and Oceania
|
In January 2018, F. Hoffmann-La Roche Ltd launched Cobas Plasma, Separation Card. This new solution is a stable and easy-to-use sample collection device for HIV plasma viral load testing. This raises the company’s sales and product portfolio.
|
|
3.
|
Siemens Healthcare GmbH
|
Siemens Healthineers offers rapid diagnostic testing solutions designed to streamline healthcare workflows and improve patient outcomes. Their RDT offerings encompass a broad spectrum of applications, from point-of-care testing for infectious diseases to rapid blood gas analysis, empowering clinicians with timely diagnostic insights.
|
|
North America, Asia, Europe
|
In April 2021, Siemens Healthcare GmbH launched the Atellica VTLi Patient-Side Immunoassay Analyzer, which obtained the CE mark for diagnosing a heart attack. The Atellica VTLi analyzer provides high-sensitivity cardiac troponin I test results to clinicians in eight minutes. The product launch would result in increased demand for the analyzer by clinicians, and product expansion of the Atellica VTLi Patient-Side Immunoassay Analyzer in North America and Europe.
|
|
4.
|
Cardinal Health
|
Cardinal Health provides a comprehensive suite of rapid diagnostic tests catering to healthcare professionals and institutions worldwide. Their RDT portfolio includes assays for infectious diseases, cardiac markers, and women's health, delivering accurate results swiftly to support clinical decision-making and patient care.
|
|
North America, Asia-Pacific, Europe, and Middle East and Africa
|
Cardinal Health partnered with Abbott and Quidel Corporation in August, 2021 to commercialize the over-the-counter (OTC) rapid COVID-19 tests. The partnership would allow Cardinal Health to expand Cardinal Health's COVID-19 testing and surveillance offerings and be able to access Quidel's QuickVue At-Home OTC COVID-19 Test and Abbott's BinaxNOW COVID-19 Antigen Self-Test, which allow the patients to perform tests without prescription easily.
|
|
5.
|
Quidel Corporation
|
Renowned for its innovative diagnostic solutions, Quidel Corporation specializes in rapid point-of-care testing for various medical conditions. From flu and respiratory infections to gastrointestinal ailments and beyond, Quidel's RDT products offer rapid, reliable results, enhancing diagnostic efficiency across diverse healthcare settings.
|
|
North America, Asia-Pacific, Europe, and Middle East and Africa
|
In November 2021, the Quidel Corporation received emergency approval from the Food and Drug Administration (FDA) for the novel Sofia Q Rapid Antigen Test Device. The approval was made immediately to add the Sofia Q to its latest product range, along with the Sofia and Sofia 2 line of Fluorescent Immunoassay Analyzers (FIA). The approval received would allow the Sofia Q rapid antigen test device to be used in telemedicine and home markets.
|
Conclusion
The rapid diagnostic tests (RDTs) market is dominated by key players such as Abbott, F. Hoffmann-La Roche Ltd., Siemens Healthcare GmbH, Cardinal Health, and Quidel Corporation. These companies offer diverse RDT solutions, contributing significantly to infectious disease management and public health initiatives worldwide. Their focus on innovation, quality, and broad geographical coverage empowers healthcare professionals with timely diagnostic insights to initiate appropriate treatment, prevent disease transmission, and improve patient outcomes. As the demand for rapid and accurate diagnostic solutions grows, these companies are poised to play a pivotal role in addressing global healthcare challenges and advancing medical diagnostics.
